25 May 2013
Keywords: sbi, licenses, anti-ilt7, protein, medimmune, biologics, unit
Article | 29 September 2008
MedImmune, the biologics unit of Anglo-Swedish drug major AstraZeneca, has entered into a licensing and collaboration agreement to develop and
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 September 2008
22 September 2008
24 May 2013
© 2013 thepharmaletter.com